Heron Therapeutics, Inc. has adopted a Section 382 rights plan to protect its net operating loss carryforwards and tax attributes.
The plan aims to safeguard over $1.37 billion of U.S. federal NOLs for future use in offsetting taxable income.
The Rights Plan prevents any single investor or group from acquiring 4.99% or more of Heron's outstanding common stock.
Purpose of Rights Plan
Protect significant potential value of NOLs to offset pre-tax income and support growth plans.
Effective Date
Rights Plan became effective on August 14, 2025, and will expire one year from that date unless extended by the Board.
Board Approval
The Board unanimously approved the adoption of the Rights Plan to preserve NOLs and tax attributes.
- Heron Therapeutics aims to secure its financial future by safeguarding valuable tax attributes.
- The Rights Plan serves to deter ownership changes that could limit the company's ability to utilize NOLs effectively.
The adoption of the Tax Benefits Preservation Plan underscores Heron's commitment to maximizing shareholder value and strategic growth.